MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Feb 21

PMID 35186709

Authors

Maria Papaioannou

Angeliki G Chorti

Anthoula Chatzikyriakidou

Kleanthis Giannoulis

Sohail Bakkar

Theodosios S Papavramidis

Affiliations

Soon will be listed here.

Abstract

Introduction: Papillary thyroid cancer (PTC) accounts for up to 80% of thyroid malignancies. New diagnostic and therapeutic options are suggested including innovative molecular methods. MicroRNAs (miRNAs) are nonprotein coding single-stranded RNAs that regulate many cell processes. The aim of the present study is to review the deregulated miRNAs associated with PTCs.

Methods: A bibliographic research was conducted, resulting in 272 articles referred to miRNAs and PTC. Regarding our exclusion criteria, 183 articles were finally included in our review.

Results: A remarkably large number of miRNAs have been found to be deregulated during PTC manifestation in the literature. The deregulated miRNAs are detected in tissue samples, serum/plasma, and FNA samples of patients with PTC. These miRNAs are related to several molecular pathways, involving genes and proteins responsible for important biological processes. MiRNA deregulation is associated with tumor aggressiveness, including larger tumor size, multifocality, extrathyroidal extension, lymphovascular invasion, lymph node and distant metastasis, and advanced tumor node metastasis stage.

Conclusion: MiRNAs are proposed as new diagnostic and therapeutic tools regarding PTC. They could be essential biomarkers for PTC diagnosis applied in serum and FNA samples, while their contribution to prognosis is of great importance.

Citing Articles

Could microRNA Analysis Help in the Management of Medullary Thyroid Cancer?.

Febrero B, Ros-Madrid I, Revilla-Nuin B, Abellan M, Ruiz-Manzanera J, Gomez J Cancers (Basel). 2025; 17(4).

PMID: 40002224 PMC: 11853104. DOI: 10.3390/cancers17040629.

The Application of microRNAs in Papillary Thyroid Cancer: A Bibliometric and Visualized Analysis.

Zhang T, Yuan B, Yu S Int J Gen Med. 2024; 17:4681-4699.

PMID: 39429957 PMC: 11490214. DOI: 10.2147/IJGM.S487239.

MicroRNA Profiling in Papillary Thyroid Cancer.

Armos R, Bojtor B, Papp M, Illyes I, Lengyel B, Szili B Int J Mol Sci. 2024; 25(17).

PMID: 39273308 PMC: 11395536. DOI: 10.3390/ijms25179362.

Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated Thyroid Carcinomas.

Matos M, Pinto M, Alves M, Canberk S, Goncalves A, Bugalho M Genes (Basel). 2024; 15(3).

PMID: 38540448 PMC: 10970297. DOI: 10.3390/genes15030389.

miR-331-5p Affects Motility of Thyroid Cancer Cell Lines and Regulates BID Expression.

Orlandella F, Imperlini E, Pane K, Luciano N, Braile M, De Stefano A Biomedicines. 2024; 12(3).

PMID: 38540271 PMC: 10968654. DOI: 10.3390/biomedicines12030658.

References

Salajegheh A, Vosgha H, Md Rahman A, Amin M, Smith R, Lam A . Modulatory role of miR-205 in angiogenesis and progression of thyroid cancer. J Mol Endocrinol. 2015; 55(3):183-96. DOI: 10.1530/JME-15-0182. View

Liu X, He M, Hou Y, Liang B, Zhao L, Ma S . Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma. Oncol Rep. 2013; 29(4):1415-20. DOI: 10.3892/or.2013.2263. View

Hua K, Jin J, Zhang H, Zhao B, Wu C, Xu H . MicroRNA-7 inhibits proliferation, migration and invasion of thyroid papillary cancer cells via targeting CKS2. Int J Oncol. 2016; 49(4):1531-1540. DOI: 10.3892/ijo.2016.3660. View

Saiselet M, Gacquer D, Spinette A, Craciun L, Decaussin-Petrucci M, Andry G . New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer. BMC Genomics. 2015; 16:828. PMC: 4618137. DOI: 10.1186/s12864-015-2082-3. View

Huang Y, Yu S, Cao S, Yin Y, Hong S, Guan H . MicroRNA-222 Promotes Invasion and Metastasis of Papillary Thyroid Cancer Through Targeting Protein Phosphatase 2 Regulatory Subunit B Alpha Expression. Thyroid. 2018; 28(9):1162-1173. DOI: 10.1089/thy.2017.0665. View

Sun W, Lan X, Zhang H, Wang Z, Dong W, He L . NEAT1_2 functions as a competing endogenous RNA to regulate ATAD2 expression by sponging microRNA-106b-5p in papillary thyroid cancer. Cell Death Dis. 2018; 9(3):380. PMC: 5841310. DOI: 10.1038/s41419-018-0418-z. View

Acibucu F, Dokmetas H, Tutar Y, Elagoz S, Kilicli F . Correlations between the expression levels of micro-RNA146b, 221, 222 and p27Kip1 protein mRNA and the clinicopathologic parameters in papillary thyroid cancers. Exp Clin Endocrinol Diabetes. 2014; 122(3):137-43. DOI: 10.1055/s-0034-1367025. View

Al-Abdallah A, Jahanbani I, Mehdawi H, Ali R, Al-Brahim N, Mojiminiyi O . Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma. Exp Mol Pathol. 2020; 113:104379. DOI: 10.1016/j.yexmp.2020.104379. View

Sun W, Lan X, Wang Z, Dong W, He L, Zhang T . MicroRNA-144 inhibits proliferation by targeting WW domain-containing transcription regulator protein 1 in papillary thyroid cancer. Oncol Lett. 2018; 15(1):1007-1013. PMC: 5772735. DOI: 10.3892/ol.2017.7440. View

10.

Minna E, Romeo P, Dugo M, De Cecco L, Todoerti K, Pilotti S . miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. Oncotarget. 2016; 7(11):12731-47. PMC: 4914318. DOI: 10.18632/oncotarget.7262. View

11.

Liu F, Lou K, Zhao X, Zhang J, Chen W, Qian Y . miR-214 regulates papillary thyroid carcinoma cell proliferation and metastasis by targeting PSMD10. Int J Mol Med. 2018; 42(6):3027-3036. PMC: 6202080. DOI: 10.3892/ijmm.2018.3902. View

12.

Wen D, Pan D, Lin P, Mo Q, Wei Y, Luo Y . Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing. Mol Med Rep. 2018; 18(3):2631-2642. PMC: 6102695. DOI: 10.3892/mmr.2018.9247. View

13.

Xiong Y, Kotian S, Zeiger M, Zhang L, Kebebew E . miR-126-3p Inhibits Thyroid Cancer Cell Growth and Metastasis, and Is Associated with Aggressive Thyroid Cancer. PLoS One. 2015; 10(8):e0130496. PMC: 4526518. DOI: 10.1371/journal.pone.0130496. View

14.

Huang C, Cai Z, Huang M, Mao C, Zhang Q, Lin Y . miR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor α. J Clin Endocrinol Metab. 2014; 100(2):E204-13. PMC: 4318892. DOI: 10.1210/jc.2014-2883. View

15.

Sun M, Fang S, Li W, Li C, Wang L, Wang F . Associations of miR-146a and miR-146b expression and clinical characteristics in papillary thyroid carcinoma. Cancer Biomark. 2014; 15(1):33-40. DOI: 10.3233/CBM-140431. View

16.

Jin H, Liang Y, Wang X, Zhu J, Sun R, Chen P . Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer. Med Oncol. 2014; 31(10):221. DOI: 10.1007/s12032-014-0221-3. View

17.

Zhu Y, Zheng K, Zhang H, Chen L, Wu K, Ren C . [Expression of microRNA-155 in papillary thyroid carcinoma and its clinical significance]. Nan Fang Yi Ke Da Xue Xue Bao. 2016; 36(10):1364-1368. View

18.

Pu Y, Xiang J, Zhang J . RETRACTED: KDM5B-mediated microRNA-448 up-regulation restrains papillary thyroid cancer cell progression and slows down tumor growth via TGIF1 repression. Life Sci. 2020; 250:117519. DOI: 10.1016/j.lfs.2020.117519. View

19.

Jiang X, Zhang H, Chen Y, Peng L . [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features]. Zhonghua Bing Li Xue Za Zhi. 2017; 46(3):160-165. DOI: 10.3760/cma.j.issn.0529-5807.2017.03.004. View

20.

Pilli T, Cantara S, Marzocchi C, Cardinale S, Santini C, Cevenini G . Diagnostic Value of Circulating microRNA-95 and -190 in the Differential Diagnosis of Thyroid Nodules: A Validation Study in 1000 Consecutive Patients. Thyroid. 2017; 27(8):1053-1057. DOI: 10.1089/thy.2017.0035. View